Drug name - Zolinza

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7456219 MERCK Polymorphs of suberoylanilide hydroxamic acid
Mar, 2027

(4 years from now)

CN1901895A MERCK Methods Of Treating Cancer With Hdac Inhibitors
Aug, 2010

(12 years ago)

CN102188415A MERCK Method Of Treating Cancer With Hdac Inhibitor
Mar, 2013

(9 years ago)

CN1870985B MERCK Method Of Hdac Inhibitor For Treating Cancer
Oct, 2013

(8 years ago)

CN1870985A MERCK Method For Treating Cancer With Hdac Inhibitor
Oct, 2013

(8 years ago)

CN101259120A MERCK Methods Of Inducing Terminal Differentiation
Mar, 2023

(4 months from now)

CN101259120B MERCK Suberoylanilide Hydroxamic Acid Or A Pharmaceutically Acceptable Salt Thereof In Preparing A Medicament For Inducing Terminal Differentiation
Mar, 2023

(4 months from now)

IN236771B MERCK A Pharmaceutical Composition For Oral Administration
Mar, 2023

(4 months from now)

IN200402721P1 MERCK A Pharmaceutical Composition For Oral Administration
Mar, 2023

(4 months from now)

EP1487426A4 MERCK Methods Of Inducing Terminal Differentiation
Jan, 2019

(3 years ago)

EP1487426A2 MERCK Methods Of Inducing Terminal Differentiation
Jan, 2019

(3 years ago)

EP1487426B1 MERCK Methods Of Inducing Terminal Differentiation
Jan, 2019

(3 years ago)

EP2082737B1 MERCK Methods Of Inducing Terminal Differentiation
Mar, 2023

(4 months from now)

EP2082737A2 MERCK Methods Of Inducing Terminal Differentiation
Mar, 2023

(4 months from now)

EP2082737A3 MERCK Methods Of Inducing Terminal Differentiation
Mar, 2023

(4 months from now)

EP1663194A4 MERCK Method Of Treating Cancer With Hdac Inhibitors
Aug, 2024

(1 year, 10 months from now)

EP1663194A2 MERCK Use Of Saha For Treating Mesothelioma
Aug, 2024

(1 year, 10 months from now)

EP1663194B1 MERCK Use Of Saha For Treating Mesothelioma
Aug, 2024

(1 year, 10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7652069 MERCK Polymorphs of suberoylanilide hydroxamic acid Mar, 2023

(4 months from now)

US8067472 MERCK Methods of treating Hodgkin's and non-Hodgkin's lymphoma Mar, 2023

(4 months from now)

US8101663 MERCK Polymorphs of suberoylanilide hydroxamic acid Mar, 2023

(4 months from now)

US7732490 MERCK Methods of treating cancer Mar, 2023

(4 months from now)

US7851509 MERCK Polymorphs of suberoylanilide hydroxamic acid Feb, 2024

(1 year, 4 months from now)

US7399787 MERCK Methods of treating cancer with HDAC inhibitors Feb, 2025

(2 years from now)

US8093295 MERCK Formulations of suberoylanilide hydroxamic acid and methods for producing the same May, 2026

(3 years from now)

US8450372 MERCK Formulations of suberoylanilide hydroxamic acid and methods for producing same Mar, 2028

(5 years from now)

Drugs and Companies using VORINOSTAT ingredient

Treatment: Treatment of cutaneous manifestations in patients wtih cutaneous t-cell lymphoma (ctcl)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.